141 related articles for article (PubMed ID: 19632769)
1. Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Bil J; Zapala L; Nowis D; Jakobisiak M; Golab J
Cancer Lett; 2010 Feb; 288(1):57-67. PubMed ID: 19632769
[TBL] [Abstract][Full Text] [Related]
2. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
Will Y; Dykens JA; Nadanaciva S; Hirakawa B; Jamieson J; Marroquin LD; Hynes J; Patyna S; Jessen BA
Toxicol Sci; 2008 Nov; 106(1):153-61. PubMed ID: 18664550
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
4. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro.
Krusch M; Salih J; Schlicke M; Baessler T; Kampa KM; Mayer F; Salih HR
J Immunol; 2009 Dec; 183(12):8286-94. PubMed ID: 20007592
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Vogl UM; Berger W; Micksche M; Pirker C; Lamm W; Pichelmeyer O; Zielinski CC; Schmidinger M
Cancer Lett; 2009 May; 277(2):218-26. PubMed ID: 19171421
[TBL] [Abstract][Full Text] [Related]
6. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
Cheng H; Kari G; Dicker AP; Rodeck U; Koch WJ; Force T
Circ Res; 2011 Dec; 109(12):1401-9. PubMed ID: 21998323
[TBL] [Abstract][Full Text] [Related]
7. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
[TBL] [Abstract][Full Text] [Related]
8. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
[TBL] [Abstract][Full Text] [Related]
9. Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo.
Issat T; Nowis D; Legat M; Makowski M; Klejman MP; Urbanski J; Skierski J; Koronkiewicz M; Stoklosa T; Brzezinska A; Bil J; Gietka J; Jakóbisiak M; Golab J
Int J Oncol; 2007 Jun; 30(6):1413-25. PubMed ID: 17487362
[TBL] [Abstract][Full Text] [Related]
10. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
Sulkes A
Isr Med Assoc J; 2010 Oct; 12(10):628-32. PubMed ID: 21090521
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.
Shibayama Y; Nakano K; Maeda H; Taguchi M; Ikeda R; Sugawara M; Iseki K; Takeda Y; Yamada K
Biol Pharm Bull; 2011; 34(3):433-5. PubMed ID: 21372398
[TBL] [Abstract][Full Text] [Related]
12. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
13. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2.
Huang Y; Wang Y; Li Y; Guo K; He Y
J Cancer Res Clin Oncol; 2011 May; 137(5):829-37. PubMed ID: 20809412
[TBL] [Abstract][Full Text] [Related]
14. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.
Wong WW; Tan MM; Xia Z; Dimitroulakos J; Minden MD; Penn LZ
Clin Cancer Res; 2001 Jul; 7(7):2067-75. PubMed ID: 11448925
[TBL] [Abstract][Full Text] [Related]
15. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Kah J; Wüstenberg A; Keller AD; Sirma H; Montalbano R; Ocker M; Volz T; Dandri M; Tiegs G; Sass G
Oncol Rep; 2012 Sep; 28(3):1077-83. PubMed ID: 22710979
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
[TBL] [Abstract][Full Text] [Related]
17. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
18. Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.
Singhal SS; Sehrawat A; Sahu M; Singhal P; Vatsyayan R; Rao Lelsani PC; Yadav S; Awasthi S
Int J Cancer; 2010 Mar; 126(6):1327-38. PubMed ID: 19626587
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.
Hipp MM; Hilf N; Walter S; Werth D; Brauer KM; Radsak MP; Weinschenk T; Singh-Jasuja H; Brossart P
Blood; 2008 Jun; 111(12):5610-20. PubMed ID: 18310500
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
